Advocacy intelligence hub — real-time data for patient organizations
Tianjin Medical University General Hospital — EARLY_PHASE1
Tang-Du Hospital — NA
Shanghai Pulmonary Hospital, Shanghai, China — PHASE2
Tianjin Medical University Cancer Institute and Hospital — PHASE2
Centre hospitalier de l'Université de Montréal (CHUM) — PHASE2
First Affiliated Hospital of Ningbo University — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs15
Alecensa
Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)
Ibtrozi
Nuvation Bio Inc.
Alunbrig
Takeda Development Center Americas, Inc.
ZYKADIA
Novartis Pharmaceuticals Corp.
Avastin
Genentech, Inc.
Iressa
AstraZeneca Pharmaceuticals LP
Yervoy
Bristol-Myers Squibb Company
Tagrisso
AstraZeneca Pharmaceuticals LP
Lumakras
Amgen Inc.
ROZLYTREK
Genentech, Inc.
TAFINLAR
Novartis Pharmaceuticals Corp.
VIZIMPRO
Pfizer, Inc.
LORBRENA
Pfizer, Inc.
GAVRETO�
Rigel Pharmaceuticals, Inc.
Tepmetko
EMD Serono, Inc.
Ibtrozi
(taletrectinib)Orphan drugNuvation Bio Inc.
12.1 Mechanism of Action Taletrectinib is an inhibitor of tyrosine kinase ROS1, including ROS1 resistance mutations. Taletrectinib also showed inhibit...
Augtyro
(repotrectinib)Orphan drugBristol Myers Squibb Company
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine ...
Braftovi
(encorafenib)Orphan drugArray BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)
12.1 Mechanism of Action Encorafenib is a kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in vitro cell-free assays wi...
Tepmetko
(tepotinib)Orphan drugEMD Serono, Inc.
12.1 Mechanism of Action Tepotinib is a kinase inhibitor that targets MET, including variants with exon 14 skipping alterations. Tepotinib inhibits he...
LORBRENA
(Lorlatinib)Orphan drugPfizer, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK...
VIZIMPRO
(dacomitinib)Orphan drugPfizer, Inc.
12.1 Mechanism of Action Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and cert...
Gilotrif
(afatinib)Orphan drugBoehringer Ingelheim Pharmaceuticals, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyr...
Alecensa
(alectinib)Orphan drugHoffmann-La Roche, Inc. (c/o Genentech, Inc.)
12.1 Mechanism of Action Alectinib is a tyrosine kinase inhibitor that targets ALK and RET. In nonclinical studies, alectinib inhibited ALK phosphoryl...
Browse all NON RARE IN EUROPE: Non-small cell lung cancer news →
Daniel SW Tan
National Cancer Centre, Singapore
Athanassios (Ethan) Argiris
ECOG-ACRIN Cancer Research Group
📍 Mobile, Alabama
Neal Flomenberg, MD, M.D
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
📍 PHILADELPHIA, PA
Si-Yu Wang, MD
Sun Yat-sen University
Charles Theuer, MD, PhD, MD
Tracon Pharmaceuticals Inc.
📍 SAN DIEGO, CA
Armando Santoro, MD
Istituto Clinico Humanitas
View all NON RARE IN EUROPE: Non-small cell lung cancer specialists →